NASD · Healthcare · Biotechnology · USA
Arbutus Biopharma Corp is a small cap company (market value between $300 million and $2 billion) in the Biotechnology industry.
Arbutus Biopharma is a clinical-stage biopharmaceutical company developing treatments for chronic hepatitis B. The company is advancing imdusiran, a subcutaneously-delivered RNAi therapeutic, and an oral PD-L1 inhibitor, both in clinical trials for hepatitis B patients. Arbutus also holds intellectual property rights to lipid nanoparticle technology, which it defends through litigation and licenses to third parties.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Arbutus Biopharma Corp stock.
Undervalued: intrinsic value $20.09 per share, market price $4.21, margin of safety 79.0% (as of 2026-10-30).
Discounting its cash flows at 9.4% (average of 3 methods) values the shares at $20.09; the price of $4.21 is 79% below that value, and 76% of that value comes from beyond year five.
Leak Score: 69/100 on 9 of 12 signals (Faint Leak).
17 more funds hold it; the full list is part of the paid plan.
ABUS is undervalued (as of the 2026-10-30 close). Discounting its cash flows at 9.4% (average of 3 methods) values the shares at $20.09; the price of $4.21 is 79% below that value, and 76% of that value comes from beyond year five.
$20.09 per share (as of the 2026-10-30 close), against a market price of $4.21. That is a margin of safety of 79.0%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
69 out of 100, which we rate "Faint Leak", on 9 of 12 value investing signals.